GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » COGS-to-Revenue

Ascentage Pharma Group International (FRA:36X) COGS-to-Revenue : 0.09 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International COGS-to-Revenue?

Ascentage Pharma Group International's Cost of Goods Sold for the six months ended in Dec. 2024 was €1.8 Mil. Its Revenue for the six months ended in Dec. 2024 was €20.6 Mil.

Ascentage Pharma Group International's COGS to Revenue for the six months ended in Dec. 2024 was 0.09.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ascentage Pharma Group International's Gross Margin % for the six months ended in Dec. 2024 was 91.06%.

Ascentage Pharma Group International COGS-to-Revenue Historical Data

The historical data trend for Ascentage Pharma Group International's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International COGS-to-Revenue Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.16 0.12 0.10 0.14 0.03

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.13 0.16 0.02 0.09

Ascentage Pharma Group International COGS-to-Revenue Calculation

Ascentage Pharma Group International's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3.815 / 128.631
=0.03

Ascentage Pharma Group International's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.84 / 20.581
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International  (FRA:36X) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ascentage Pharma Group International's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.84 / 20.581
=91.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Ascentage Pharma Group International COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:09606 HKSE:09969 HKSE:02696 HKSE:01952 HKSE:02162 HKSE:01548 HKSE:06826 HKSE:02410 HKSE:00775 HKSE:02171 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AAPG:USA 06855:Hong Kong 36X0:Germany 36X0:Germany 36X:Germany
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Website
https://www.ascentagepharma.com
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines